Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03226769 · ClinicalTrials.gov registry record · NA

Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease

A NA study, sponsored by Allergan.

Completed
Registry status
NA
Development phase
57
Enrollment target

NCT03226769 is a NA study that has completed, run by Allergan. The registered enrollment target is 57 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03226769, a NA study, has completed, sponsored by Allergan.

COMPLETED
Registry status
NA
Development phase
57 participants
Enrollment target

Study Summary

This study will compare the safety and efficacy of TrueTear™ to standardized moist heat compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).

Interventions

  • DEVICE TrueTear™
  • DEVICE Thermalon Dry Eye Compress

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2017-07-26
Est. Completion 2017-12-12
Phase NA

Sponsor

Allergan

314 total trials

What the Registry Record Tells You About NCT03226769

The ClinicalTrials.gov registry entry for NCT03226769 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which TrueTear™ is the first listed.

NCT03226769 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03226769 about?

NCT03226769 is a clinical study titled "Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease". This study will compare the safety and efficacy of TrueTear™ to standardized moist heat compress (Thermalon® Dry Eye Compress) for the treatment of Meibomian Gland Disease (MGD).

What is the current status of trial NCT03226769?

This trial is currently completed. It is a NA study. The enrollment target is 57 participants. The study started on 2017-07-26. Estimated completion is 2017-12-12.

What interventions are being tested in trial NCT03226769?

The interventions under investigation include: TrueTear™ (DEVICE), Thermalon Dry Eye Compress (DEVICE).

Who is sponsoring clinical trial NCT03226769?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.